Page 373 - Binder2

Because in the next era of medicine, delivery isn’t just a
means to an end.

It’s part of the cure.

7.1 – The Collapse of Clinical Infrastructure

For decades, the delivery of biologic therapies has
depended on an ecosystem built for complexity: hospital
infusion centers, specialty pharmacies, cold-chain logistics,
insurance pre-authorizations, and trained medical staff to
oversee every administration. This infrastructure wasn’t
just a response to the fragility of the drugs—it became part
of the business model. Infusions generate facility fees.
Specialty drugs justify prior authorizations. Every step of
complexity creates an opportunity to charge, monitor, and
gatekeep.

But that model was built around injectable proteins with a
narrow stability range and a high risk of immune rejection.
It was never optimized for patient convenience, global
access, or long-term immune harmony. It was optimized for
control.

Edible, shelf-stable biologics render much of that
infrastructure obsolete.

Plant-grown proteins—delivered in freeze-dried capsules,
powders, or food forms—don’t require refrigeration. They
don’t require needles, infusion chairs, or clinician
supervision. They can be stored at room temperature,
administered at home, and mailed directly to patients. In
other words, the infrastructure isn’t just optional—it’s
actively in the way.

371